Table 2

Statistical differences between patients with unexplained female sterility, patients with RPL and control subjects


Hcy (μM/ml)
p
Serum folate (ng/ml)
P
Serum vit. B 12 (pg/ml)
p
MTHFR C677T heterozigosity
p
MTHFR C677T homozigosity
p

UFS vs CG
21.05 ± 8.78 vs 7.85 ± 3.31
<0.01, s
6.70 ± 4.50 vs 20.10 ± 9.44
<0.01, s
648 ± 162 vs 664 ± 175
0.35, ns
5/20 vs 9/20
0.32, ns
15/20 vs 3/20
<0.01, s
UFS vs RPL
21.05 ± 8.78 vs 19.20 ± 6.14
0.44, ns
6.70 ± 4.50 vs 6.10 ± 2.81
0.007, s
648 ± 162 vs 608 ± 154
0.42, ns
5/20 vs 3/20
0.69, ns
15/20 vs 17/20
0.69, ns
RPL vs CG
19.20 ± 6.14 vs 7.85 ± 3.31
<0.01, s
6.10 ± 2.81 vs 20.10 ± 9.44
<0.01, s
608 ± 154 vs vs 664 ± 175
0.20, ns
3/20 vs 9/20
0.08, ns
17/20 vs 3/20
<0.01, s

Hcy: homocysteine

MTHFR: methylenetetrahydrofolate reductase

UFS: unexplained female sterility group

RPL: recurrent pregnancy loss group

CG: control group

ns: not significant

s: significant

D'Uva et al. Thrombosis Journal 2007 5:10   doi:10.1186/1477-9560-5-10